US HHS grants $1.4bn for Covid-19 vaccines development
23 Aug 2023
Vaccine
Preview
Source: Pharmaceutical Technology
Regeneron will receive $326m to develop a new monoclonal antibody to prevent Covid-19 infection. Credit: Viacheslav Lopatin / Shutterstock.com.
The US Department of Health and Human Services (HHS) has made a grant of more than $1.4bn to Project NextGen to facilitate the development of new vaccines and therapeutics for Covid-19.
Project NextGen is a $5bn programme led by the Administration for Strategic Preparedness and Response’s (ASPR) Biomedical Advanced Research and Development Authority (BARDA) in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID)Infectious Diseases (NIAID).
Recommended Reports
Preview
Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - Ribociclib Succinate in Pediatric Diffuse Intrinsic Pontine Glioma GlobalData
Preview
Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - pneumococcal (24-valent) vaccine GlobalData
View allCompanies IntelligenceThe National Institute of Allergy and Infectious DiseasesJ LabsICON Government and Public Health Solutions, Inc.Regeneron GmbHHH&S LtdView all
This initiative focuses on progressing vaccines and therapies into clinical trials, and their subsequent regulatory review and commercialisation for use by Americans.
The latest funding includes a $1bn award to four BARDA clinical trial partners, ICON Government and Public Health Solutions, Pharm-Olam, Technical Resources and Rho Federal Systems, to carry out Phase IIb clinical trials of a vaccine.
Regeneron will receive $326m to develop a new monoclonal antibody to prevent Covid-19 infection.
Global Health Investment (GHIC) will be awarded $100m to advance technologies to expedite future responses.
There is also an award of $10m to Johnson & Johnson Innovation (JLABS) for the Blue Knight initiative, a collaboration between BARDA and JLABS.
HHS Secretary Xavier Becerra stated: “Project NextGen is a key part of the Biden-Harris administration’s commitment to keeping people safe from Covid-19 variants.
“These awards are a catalyst for the programme – kickstarting efforts to more quickly develop vaccines and continue to ensure availability of effective treatments.”
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.